Preparation and Evaluation of Inhalable Sustained Release Sildenafil Citrate Solid Lipid Microparticles Dispersions

Authors

  • A. A.Yas

  • Ali Al - Jipouri

Keywords:

sildenafil citrate, glyceryl behenate, closed melt method, solid lipid microparticles dispersions, dry powder inhaler

Abstract

This is a preliminary study utilizing drug targeting approach for developing sildenafil citrate (SFC) pulmonary delivery system, a first - line for pulmonary arterial hypertension (PAH) treatment and hence reducing the dose and the side effects. The closed melt method was employed for preparing SFC - solid lipid microparticles dispersions (SFC - SLMDs), a non - solvent technique aid in the production of drug - matrix dispersions with sustained release properties. Glyceryl behenate (GB) (Compritol® 888 ATO) was used as the retarding matrix and the results shown that as its ratio increase there was a decrease in the fine particle fraction, an increase in the drug content and a prolong drug release pattern. The best model fit the release data was Higuchi - Matrix model which indicates drug diffusion - controlled releasing mechanism. Thus, inhaled SFC - SLMDs dry powder will improve PAH treatment via drug localization at low doses and reducing the administration frequency.

How to Cite

Preparation and Evaluation of Inhalable Sustained Release Sildenafil Citrate Solid Lipid Microparticles Dispersions. (2014). Global Journal of Medical Research, 14(38), 1-5. https://medicalresearchjournal.org/index.php/GJMR/article/view/

Author Biography

A. A.Yas

Dr. A. A. Yas, a dedicated pharmaceutical scientist, is affiliated with the College of Pharmacy at Tikrit University in Iraq. With a PhD in Pharmaceutics specializing in Pulmonary Drug Delivery, Dr. Yas has focused on developing innovative drug delivery systems. His research includes the preparation and evaluation of inhalable sustained release sildenafil citrate solid lipid microparticles dispersions, as well as the optimization of liposomal ketotifen fumarate dry powder using response surface methodology. These works demonstrate his commitment to advancing pulmonary drug delivery and improving therapeutic outcomes. Dr. Yas continues to contribute to the field of pharmaceutics through his academic and research endeavors at Tikrit University.

References

Lyn Frumkin (2012) The Pharmacological Treatment of Pulmonary Arterial Hypertension. 64(3), 583-620. https://doi.org/10.1124/pr.111.005587

Marie-Camille Chaumais, Swanny Perrin, Olivier Sitbon, Gérald Simonneau, Marc Humbert, David Montani (2013) Pharmacokinetic evaluation of sildenafil as a pulmonary hypertension treatment. 9(9), 1193-1205. https://doi.org/10.1517/17425255.2013.804063

N. Labiris, M. Dolovich (2003) Pulmonary drug delivery. Part I: Physiological factors affecting therapeutic effectiveness of aerosolized medications. 56(6), 588-599. https://doi.org/10.1046/j.1365-2125.2003.01892.x

Beck M, Kleimann P, Gessler T, Seeger W, Kissel T, Schmehl T (2012) Nebulization Performance of Biodegradable Sildenafil - Loaded Nanoparticles using the Aeroneb® Pro: Formulation Aspects and Nanoparticle Stability to Nebulization.

Preparation and Evaluation of Inhalable Sustained Release Sildenafil Citrate Solid Lipid Microparticles Dispersions

Published

2014-08-18

How to Cite

Preparation and Evaluation of Inhalable Sustained Release Sildenafil Citrate Solid Lipid Microparticles Dispersions. (2014). Global Journal of Medical Research, 14(38), 1-5. https://medicalresearchjournal.org/index.php/GJMR/article/view/